Bosch John Roderick Ten Sells 2,832 Shares of Billiontoone (NASDAQ:BLLN) Stock

Posted by Geri Gentry on Jun 19th, 2026

Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) insider Bosch John Roderick Ten sold 2,832 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $101.47, for a total transaction of $287,363.04. Following the sale, the insider owned 34,968 shares of the company’s stock, valued at approximately $3,548,202.96. This represents a 7.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Trading Up 5.8%

Billiontoone stock opened at $105.15 on Friday. The business has a 50-day simple moving average of $89.56 and a two-hundred day simple moving average of $87.22. The company has a market cap of $4.84 billion and a P/E ratio of 191.18. Billiontoone, Inc. has a 52-week low of $61.96 and a 52-week high of $138.70. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18.

Billiontoone (NASDAQ:BLLN – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.33. The business had revenue of $108.39 million during the quarter, compared to the consensus estimate of $95.81 million. Billiontoone’s revenue for the quarter was up 83.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.39) EPS. Analysts predict that Billiontoone, Inc. will post 0.93 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BLLN. JPMorgan Chase & Co. increased their price target on shares of Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Weiss Ratings downgraded Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 5th. Wall Street Zen raised Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. BTIG Research decreased their price objective on Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Finally, Wells Fargo & Company lowered their price objective on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 5th. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $125.29.

Get Our Latest Analysis on BLLN

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BLLN. Adams Street Partners LLC purchased a new stake in Billiontoone in the 4th quarter worth $140,063,000. Baillie Gifford & Co. purchased a new position in shares of Billiontoone in the fourth quarter valued at about $103,786,000. Price T Rowe Associates Inc. MD bought a new position in shares of Billiontoone in the fourth quarter worth about $39,717,000. JPMorgan Chase & Co. purchased a new stake in shares of Billiontoone during the fourth quarter worth about $32,078,000. Finally, Wasatch Advisors LP purchased a new stake in shares of Billiontoone during the first quarter worth about $29,179,000.

About Billiontoone

(Get Free Report)

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.